Article
Rheumatology
Allan Gibofsky, Dorothy McCabe
Summary: US rheumatologists generally have a good understanding and acceptance of biosimilar products, especially when initiating treatment in biologic-naive individuals. However, they are hesitant to switch patients who are responding well to reference products to biosimilars. Additional education on biosimilars is needed to better inform treatment decisions by rheumatologists.
Article
Medicine, General & Internal
David L. Carl, Yannic Laube, Miquel Serra-Burriel, Huseyin Naci, Wolf-Dieter Ludwig, Kerstin N. Vokinger
Summary: This study compares the uptake and prices of biosimilars in the US with two European countries (Germany and Switzerland) that have national mechanisms for drug price negotiation. The findings suggest that more biosimilars have been marketed in Germany and Switzerland than in the US. Counteracting anticompetitive practices in the US could promote the entry of biosimilars into the market and lower healthcare costs.
Article
Oncology
Allison R. Kolbe, Aaron Kearsley, Lubna Merchant, Eva Temkin, Archita Patel, Jing Xu, Amber Jessup
Summary: The survey found that some US healthcare professionals have a limited understanding of key elements of biosimilarity, even among those who have previously prescribed biosimilars. Prescriber choice is primarily driven by formulary status, but factors such as cost savings, pharmacovigilance, patient experience, and education also play a role. Additional education on biosimilarity is needed to address gaps in knowledge and hesitancy towards biosimilars.
Review
Pharmacology & Pharmacy
Sarfaraz K. Niazi
Summary: The United States is the only country with legislation approving two classes of biosimilars. However, the interchangeability standards are more politically driven than scientifically validated, leading to confusion and mistrust in the use of biosimilars in the US.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
(2022)
Article
Health Care Sciences & Services
Andrew Mulcahy, Christine Buttorff, Kenneth Finegold, Zeid El-Kilani, Jon F. Oliver, Stephen Murphy, Amber Jessup
Summary: This study projected the savings from biosimilars in the US from 2021 to 2025. The estimated savings under the main assumptions were $38.4 billion, with a significant portion coming from downward pressure on reference biologic prices. Greater savings could be achieved if biosimilar utilization and competition were increased.
AMERICAN JOURNAL OF MANAGED CARE
(2022)
Article
Ecology
Frank Figge, Andrea Stevenson Thorpe, Jason Good
Summary: Efficient use of natural resources is crucial for sustainable use, with circular resource use being more eco-efficient. The overall eco-efficiency in circular systems is greater than the sum of individual firms' eco-efficiencies, and selecting only highly eco-efficient firms may not increase overall eco-efficiency. Resources assessment and management should be shifted from the individual to the group level in circular economy systems.
ECOLOGICAL ECONOMICS
(2021)
Article
Biotechnology & Applied Microbiology
Victor L. Van de Wiele, Reed F. Beall, Aaron S. Kesselheim, Ameet Sarpatwari
Summary: The abundance of biologic drug patents in the United States has caused delays in the availability of biosimilars.
NATURE BIOTECHNOLOGY
(2022)
Article
Medicine, General & Internal
Iris Lin, Richard Melsheimer, Rachel H. Bhak, Patrick Lefebvre, Maral DerSarkissian, Bruno Emond, Angela Lax, Catherine Nguyen, Melody Wu, Yinong Young-Xu
Summary: This study aimed to compare the treatment patterns of US veterans stable on innovator infliximab (IFX) who switched to an IFX biosimilar or remained on innovator IFX. The results showed that switchers were more likely to discontinue treatment and switch to another innovator biologic (notably back to innovator IFX) than continuers.
CURRENT MEDICAL RESEARCH AND OPINION
(2022)
Article
Economics
Robert M. Saltzman, Richard M. Bradford
Summary: In this article, we present and solve a model for the grouping and ordering of state primary elections in a U.S. presidential election cycle. Our model takes into account the attributes of each state, prioritizing states that closely align with the voting and demographic profiles of the entire country. The model clusters states into primary dates to evenly distribute the electorate over the primary season. Additionally, it considers proximity to optimize political campaign efforts. We highlight two solutions that improve upon the status quo by prioritizing states with attributes similar to the national profile and achieving a better geographic grouping and spread of voters.
SOCIO-ECONOMIC PLANNING SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Smritie Sheth, Laxmikant Vashishta, Rohit Goyal, Anurag Rathore, Narendra Chirmule
Summary: Biosimilars have provided an opportunity for global access to affordable medicines over the past two decades. The development process involves robust analytical and functional comparability, equivalent pharmacokinetic profile, and demonstrating lack of any meaningful clinical differences. Standardized processes and adherence to regulatory requirements in Asia are essential for enabling cost-effective development of biosimilars.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Gastroenterology & Hepatology
Anna M. Buchner, Yecheskel Schneider, Gary R. Lichtenstein
Summary: Biological therapy targeting tumor necrosis factor-alpha has become crucial in treating patients with inflammatory bowel disease, but high costs limit accessibility. Biosimilars offer the potential to reduce expenditures and increase availability, providing more options for patients.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Editorial Material
Surgery
Brianna L. Doby, Stuart J. Knechtle, Jayme E. Locke
Summary: This viewpoint discusses the benefits of modernization efforts for the US transplant system.
Review
Chemistry, Multidisciplinary
Aayushi S. Ditani, Pragyan Paramita Mallick, Neelima Anup, Vishakha Tambe, Suryanarayana Polaka, Pinaki Sengupta, Kuldeep Rajpoot, Rakesh K. Tekade
Summary: Biosimilars are biologics that are clinically identical to a reference standard, particularly in terms of strength, purity, and safety. A significant portion of biosimilars are developed for cancer treatment. This review article discusses various aspects of biosimilars, including their market accessibility, recent clinical trial outcomes, safety profiles, regulatory approval requirements, and associated challenges.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Environmental Sciences
Shahid Nawaz Khan, Dapeng Li, Maitiniyazi Maimaitijiang
Summary: This study proposes a method called Geographically Weighted Random Forest Regression (GWRFR) to improve crop yield prediction. The GWRFR outperforms other machine learning algorithms and can better address the spatial non-stationarity issue. This method has the potential to be used for yield prediction of other types of crops in different regions.
Article
Environmental Sciences
Sara A. Goeking, David G. Tarboton
Summary: Forest cover and streamflow are generally expected to vary inversely, but recent studies have shown that forest disturbance due to drought and insect epidemics may not lead to changes or even decrease in streamflow. This study analyzed hydrologic, climatic, and forest data for 159 watersheds in the western U.S. and found that many watersheds experienced decreased streamflow despite the decrease in forest cover. The study also identified drivers other than disturbance, precipitation, and temperature that influence streamflow change, and found that the effect of tree mortality on streamflow depends on aridity.
WATER RESOURCES RESEARCH
(2022)